Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents

Table 3

Subgroup analysis: outcomes in eyes that received early IVT-TA (group 2B) and eyes that received IVT-TA due to DME refractory to anti-VEGF treatment (group 2A).

	Group 1; ()	Group 2A; ()	Group 2B; ()	value
Mean initial BCVA	0.47 (20/59)	0.58 (20/76)	0.51 (20/65)	0.25
Mean final BCVA	0.39 (20/49)	0.60 (20/80)	0.63 (20/85)	0.0013
Mean change in BCVA	+4 letters	−1 letter	−6 letters	0.035
Mean initial CSMT	424 μm	440 μm	391 μm	0.20
Mean final CSMT	330 μm	340 μm	357 μm	0.19
Mean change in CSMT	−94 μm	−100 μm	34 μm	0.28